Jim Rouse
Director Técnico/Científico/I+D en TAYSHA GENE THERAPIES, INC. .
Origen de la red de primer grado Jim Rouse.
| Entidad | Tipo de entidad | Industria | |
|---|---|---|---|
| Public Company | Biotechnology | 13 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Jim Rouse a través de su red personal
| Empresa | Sector | Personas relacionadas | Puesto principal |
|---|---|---|---|
Jaguar Gene Therapy LLC
 Jaguar Gene Therapy LLC Medical/Nursing ServicesHealth Services Jaguar Gene Therapy LLC is a clinical stage biotechnology company based in Lake Forest, IL. Jaguar Gene Therapy LLC is dedicated to accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases. The company has a proven team of experts who have experience in bringing novel gene therapy treatments to patients and their families. Jaguar is rapidly advancing an initial pipeline of three programs, including targeting severe neurodevelopmental disorders, type 1 galactosemia, and type 1 diabetes. The company partner with Advanced Medicine Partners for manufacturing their therapeutics. Key investors include Deerfield Management Company, Arch Venture Partners, and Eli Lilly and Company. The company was founded by Daniel Gallo, and Joseph Nolan has been the CEO since 2020. | Medical/Nursing Services | Director of Finance/CFO Chairman Chief Tech/Sci/R&D Officer | |
SalioGen Therapeutics, Inc.
 SalioGen Therapeutics, Inc. BiotechnologyHealth Technology SalioGen Therapeutics, Inc. is a genetic medicine company based in Cambridge, MA. The company is advancing the Exact DNA Integration Technology (EDIT) platform, which is a mammal-derived genome engineering technology for use in potentially curative non-viral gene therapy. SalioGen Therapeutics has launched Gene Coding, a genetic medicine technology, to develop durable, broadly applicable genetic medicines using its EDIT platform. The company's mission is to transform the treatment paradigm for patients with inherited disorders. Jason F. Cole has been the CEO of the company since 2023. | Biotechnology | Director/Board Member Director/Board Member | |
| AUDENTES THERAPEUTICS, INC. | Biotechnology | General Counsel Human Resources Officer | |
| REATA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| University of Massachusetts | College/University | Undergraduate Degree | |
| DAIICHI SANKYO CO., LTD. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Neurogene, Inc.
 Neurogene, Inc. BiotechnologyHealth Technology Neurogene, Inc. focuses on developing disease modifying therapeutics for severe neurologic diseases. Its pipeline includes multiple gene therapy products for ultra-rare diseases, as well as a novel technology that has the potential for use in monogenic autism spectrum disorders and indications not well suited for gene therapy. The company was founded by Rachel McMinn in January 2018 and is headquartered in New York, NY. | Biotechnology | Director/Board Member | |
| SOLID BIOSCIENCES INC. | Biotechnology | Director/Board Member | |
| QUEST DIAGNOSTICS INCORPORATED | Services to the Health Industry | Corporate Officer/Principal | |
| Rutgers State University of New Jersey | College/University | Undergraduate Degree | |
| ANI PHARMACEUTICALS, INC. | Biotechnology | Director of Finance/CFO | |
Medocity, Inc.
 Medocity, Inc. Medical/Nursing ServicesHealth Services Medocity, Inc. develops a care platform that bridges the gap between the clinic and the patient?s home. It offers a patient-centric mobile solution that combines key aspects of disease-specific care into a platform that can be used on application and Web-based devices. The firm platform also tracks key symptoms and side effects in real time; displays reports and graphic summaries to understand the patient?s health status on a daily basis. The company is headquartered in Parsippany, NJ. | Medical/Nursing Services | Director/Board Member | |
PBM Pharmaceuticals, Inc.
 PBM Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology PBM Pharmaceuticals, Inc. manufactures pharmaceutical products. The private company is based in Charlottesville, VA. | Pharmaceuticals: Major | Director/Board Member | |
| Novartis Gene Therapies Switzerland GmbH | Director/Board Member | ||
| Vetana Animal Health, Inc. | Director/Board Member | ||
| Baxis Pharmaceuticals, Inc. | Director/Board Member | ||
| CANDEL THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Tolerion, Inc.
 Tolerion, Inc. Pharmaceuticals: MajorHealth Technology Tolerion, Inc. operates as a clinical-stage biopharmaceutical firm. It develops and commercializes therapeutics. The firm provides TOL-3034 and TOL-3052 to treat myasthenia gravis and neuromyelitis optica. The company was founded by Lawrence J. Steinman and is headquartered in South San Francisco, CA. | Pharmaceuticals: Major | Director/Board Member | |
| ACUMEN PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Octagon Finance LLC
 Octagon Finance LLC Financial ConglomeratesFinance Octagon Finance LLC provides financial services. The private company is based in Durham. | Financial Conglomerates | Corporate Officer/Principal | |
The Robert Wood Johnson Foundation
 The Robert Wood Johnson Foundation Investment Trusts/Mutual FundsMiscellaneous The Robert Wood Johnson Foundation (RWJF) is an independent philanthropic organization headquartered in Princeton, New Jersey. The firm was founded in 1972 and is dedicated solely to health. RWJF funds a wide array of programs which are working to help build a national Culture of Health. | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
| New York University | College/University | Doctorate Degree | |
| Rutgers Robert Wood Johnson Medical School | College/University | Doctorate Degree | |
| APTINYX | Pharmaceuticals: Major | Comptroller/Controller/Auditor | |
| University of the Witwatersrand | College/University | Doctorate Degree | |
| KALEIDO BIOSCIENCES, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| FREELINE THERAPEUTICS HOLDINGS PLC | Biotechnology | Chief Tech/Sci/R&D Officer | |
| BRIDGEBIO PHARMA, INC. | Biotechnology | Corporate Officer/Principal | |
| University of Illinois | College/University | Graduate Degree | |
| The University of North Carolina at Greensboro | College/University | Undergraduate Degree | |
Naurex, Inc.
 Naurex, Inc. Pharmaceuticals: MajorHealth Technology Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Stephen M. Ross School of Business | College/University | Undergraduate Degree | |
| INTELLIA THERAPEUTICS, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| Kelley School of Business | College/University | Masters Business Admin | |
| ROCKET PHARMACEUTICALS, INC. | Biotechnology | Director of Finance/CFO | |
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Medical/Nursing Services | Director/Board Member | |
Oligonucleotide Therapeutics Society, Inc.
 Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Miscellaneous Commercial Services | Director/Board Member | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Director/Board Member | |
| ALNYLAM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| VERTEX PHARMACEUTICALS INCORPORATED | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Universidad de Buenos Aires | College/University | Undergraduate Degree | |
Enterprise Mortgage Acceptance Co. LLC
 Enterprise Mortgage Acceptance Co. LLC Miscellaneous Commercial ServicesCommercial Services Enterprise Mortgage Acceptance Co. LLC provides capital and financing options for equipment financing and business loans. The private company is based in Westport, CT and has subsidiaries in the United States. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| Octagon Partners LLC | Corporate Officer/Principal | ||
Quantapore, Inc.
 Quantapore, Inc. BiotechnologyHealth Technology Quantapore, Inc. develops nanopore based nucleic acid sequencing technology products. The firm's proprietary DNA sequencing technology is based on an optically labeled nanopore which interacts via energy transfer with a labeled nucleic acid sample. The company was founded by Martin Huber and Sascha C. Dennstedt in 2009 and is headquartered in Menlo Park, CA. | Biotechnology | Director/Board Member |
Estadísticas
Internacional
| Estados Unidos | 45 |
| Japón | 2 |
| Francia | 2 |
| Suiza | 2 |
| Sudafrica | 2 |
Sectorial
| Health Technology | 27 |
| Consumer Services | 11 |
| Health Services | 5 |
| Finance | 4 |
| Commercial Services | 3 |
Operativa
| Director/Board Member | 37 |
| Corporate Officer/Principal | 26 |
| Independent Dir/Board Member | 14 |
| Director of Finance/CFO | 10 |
| Undergraduate Degree | 9 |
Las relaciones más conectadas
| Insiders | |
|---|---|
| Sean Stalfort | 28 |
| Sean Nolan | 18 |
| Philip Donenberg | 15 |
| Sukumar Nagendran | 15 |
| Mary Newman | 10 |
| Laura Sepp-Lorenzino | 9 |
| Kamran Alam | 7 |
| Tracy M. Porter | 5 |
| Alison Long | 5 |
| Fred Porter | 2 |
| Sean McAuliffe | 2 |
| Emily McGinnis | 1 |
| Hayleigh Collins | 1 |
- Bolsa de valores
- Insiders
- Jim Rouse
- Conexiones Empresas
